Scarica l'app Stockscreener
1.49
2.61%
-0.04
Dopo l'orario di chiusura:
1.50
0.01
+0.67%
Precedente Chiudi:
$1.53
Aprire:
$1.51
Volume 24 ore:
210.85K
Relative Volume:
0.56
Capitalizzazione di mercato:
$160.08M
Reddito:
-
Utile/perdita netta:
$-13.73M
Rapporto P/E:
-11.46
EPS:
-0.13
Flusso di cassa netto:
$-3.92M
1 W Prestazione:
-3.87%
1M Prestazione:
+4.20%
6M Prestazione:
+102.45%
1 anno Prestazione:
+81.60%
Intervallo 1D:
$1.43
$1.55
Intervallo di 1 settimana:
$1.43
$1.58
Portata 52W:
$0.6295
$1.91
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Nome
Tiziana Life Sciences Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta TLSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.49 | 160.08M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.36 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.75 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.50 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
538.64 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.47 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-22 | Iniziato | B. Riley Securities | Buy |
| 2018-12-17 | Iniziato | Laidlaw | Buy |
Tiziana Life Sciences Ltd Borsa (TLSA) Ultime notizie
Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Promising Penny Stocks To Consider In June 2025 - simplywall.st
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting (NASDAQ:TLSA) - Seeking Alpha
Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis - MarketScreener
Small cap wrap: Tiziana Life Sciences, Challenger Energy, Arrow Exploration... - Proactive financial news
Tiziana expands Phase 2 MS trial to fifth site, commences patient dosing - Proactive financial news
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - The Manila Times
Breakthrough Multiple Sclerosis Treatment Enters Next Phase as Weill Cornell Joins Major Clinical Trial - Stock Titan
Market movers: RH, Tiziana, Archer Aviation... - Proactive Investors
Shares of Tiziana Life Sciences (TLSA) Climb on CEO's Upcoming P - GuruFocus
Tiziana shares rise on presentation date for foralumab data - Seeking Alpha
Tiziana CEO to present clinical advances of intranasal foralumab at BIO 2025 - Proactive financial news
Tiziana Life Sciences to Present at the Bio International Convention - The Manila Times
Revolutionary Intranasal Treatment for MS and Alzheimer's: Tiziana CEO Reveals Latest Clinical Findings at BIO 2025 - Stock Titan
Tiziana Life Sciences Ltd (TLSA) Stock: A Comprehensive 52-Week Review - investchronicle.com
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% – Still a Buy? - Defense World
TLSA Advances Alzheimer's Treatment with Innovative Nasal Spray - GuruFocus
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease - marketscreener.com
Tiziana Life Sciences Announces Interview Highlighting Intranasa - GuruFocus
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease | TLSA Stock News - GuruFocus
Tiziana Life Sciences Announces Breakthrough Advancement in Moderate Alzheimer’s Treatment with Intranasal Foralumab - Nasdaq
Breakthrough: First Alzheimer's Patient Shows Improvement with Revolutionary Nasal Antibody Treatment - Stock Titan
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - BioSpace
Small cap wrap: Lancaster Resources, Cerro de Pasco, Tiziana Life Sciences, Nano One Materials... - Proactive financial news
Tiziana reports reduction in microglial activation in Alzheimer’s case treated with nasal foralumab - Proactive financial news
TLSA: Tiziana Life Sciences Study Shows Promise for Alzheimer's Treatment | TLSA Stock News - GuruFocus
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - The Manila Times
Journal Of Clinical Nuclear Medicine Publishes Results Of Tiziana’S Nasal Foralumab In Study Treating Moderate Alzheimer's Disease - MENAFN.com
Journal of Clinical Nuclear Medicine Publishes Results of - GlobeNewswire
Revolutionary Nasal Treatment Reduces Brain Inflammation in Moderate Alzheimer's Patient, Harvard Study Shows - Stock Titan
Tiziana Life Sciences chairman increases stake to over 37% - Proactive financial news
Executive Chairman Increases Stake in Tiziana Life Sciences (TLS - GuruFocus
Tiziana Life Sciences Announces Purchase of Shares by Chairman - The Manila Times
Tiziana reports promising Alzheimer’s treatment results By Investing.com - Investing.com Nigeria
Tiziana reports promising Alzheimer’s treatment results - Investing.com
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab - BioSpace
Tiziana Reports PET data sees reduced neuroinflammation in patient treated with Intranasal Therapy - Proactive Investors
Market movers: Lyft, US Gold, Tiziana Life Sciences... - Proactive Investors
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer’s patient treated with nasal foralumab - Proactive Investors
TLSA: Tiziana Life Sciences Reports Positive PET Scan Results in Alzheimer's Treatment | TLSA Stock News - GuruFocus
Tiziana stock gains on data for Alzheimer's drug (TLSA:NASDAQ) - Seeking Alpha
Tiziana Life Sciences Announces Significant Reduction In Microglia Activation In PET Scan Of Moderate Alzheimer's Patient Treated With Intranasal Foralumab - MENAFN.com
Tiziana Life Sciences Announces Significant Reduction in - GlobeNewswire
Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study - PMLiVE
Small cap wrap: Tiziana Life Sciences, Millennial Potash, Century LIthium... - Proactive financial news
Tiziana shares surge 21% on promising multiple sclerosis data - Proactive financial news
Tiziana rises on positive results in multiple sclerosis treatment study - Seeking Alpha
Tiziana reports encouraging results for nasal MS drug in early study - Proactive Investors
TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLS - GuruFocus
TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLSA Stock News - GuruFocus
Clinical Trial Success: Revolutionary Nasal Spray Halts Multiple Sclerosis Progression in Landmark Study - Stock Titan
Tiziana Life Sciences Ltd Azioni (TLSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.56%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):